Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
NCT ID: NCT00769990
Last Updated: 2017-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1/PHASE2
INTERVENTIONAL
2008-09-30
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This phase I/II trial is studying the side effects of genistein and to see how well it works in treating patients undergoing external-beam radiation therapy for pain caused by bone metastases.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To determine whether genistein is safe when administered in combination with palliative external beam radiotherapy in patients with osseous metastases.
* To determine the time to pain relief, duration of pain relief, and degree of pain relief in patients treated with this regimen.
* To determine the incidence of pathologic fractures in patients treated with this regimen.
* To determine the effect of this regimen on quality of life measures in these patients.
OUTLINE: This is a multicenter study.
Patients undergo external beam radiotherapy once daily on days 1-10. Patients also receive oral genistein once daily on days 1-60.
Patients complete pain and quality-of-life questionnaires periodically.
After completion of study therapy, patients are followed at 30 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Genistein
Patients treated with Genistein who are going to undergo palliative radiation treatments for painful boney metastases.
genistein
Genistein will be taken orally once daily as 500 mg capsules throughout the study (60 days).
radiation therapy
A course of palliative external beam radiation therapy -performed within 8 weeks prior to start of the study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
genistein
Genistein will be taken orally once daily as 500 mg capsules throughout the study (60 days).
radiation therapy
A course of palliative external beam radiation therapy -performed within 8 weeks prior to start of the study.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Breast cancer
* Lung cancer
* Kidney cancer
* Melanoma
* Prostate cancer
* Radiographic evidence\* of bone metastasis within the past 8 weeks NOTE: \*Acceptable studies include plain radiograph, radionuclide bone scan, CT scan, and MRI
* Has pain that appears to be related to the radiographically documented metastasis, in the opinion of the treating physician, AND a decision has been made by the responsible clinician that a course of palliative external beam radiotherapy is appropriate treatment
* "Worst pain score" of \> 5 on a scale of 10 as scored on the pain assessment questionnaire (BPI) (question #3: 0 = no pain; 10 = worst possible pain) OR taking narcotic medications with an oral morphine equivalent dose of \> 60 mg/day
* No painful metastases to the skull, hands, or feet
* Eligible treatment sites include any of following:
* Weight-bearing sites:
* Pelvis (excluding pubis)
* Femur
* Sacrum and/or sacroiliac joints
* Tibia
* Non-weight-bearing sites:
* Up to 5 consecutive cervical, thoracic, or lumbar vertebral bodies
* Lumbosacral spine
* Up to 3 consecutive ribs
* Humerus
* Fibula
* Radius ± ulna
* Clavicle
* Sternum
* Scapula
* Pubis
* If multiple osseous sites are treated, the treatment site is included as weight-bearing if any of the sites include the pelvis, sacrum, femur, or tibia
* Treatment of multiple osseous sites allowed only if those sites can be included in ≤ 3 treatment sites
* Patients with painful metastases that are contiguous but do not fit into the definition of a site listed above are eligible but are considered to have 2 treatment sites
* No vertebral metastases with clinical or radiographic evidence of spinal cord or cauda equina compression/effacement
* No primary hematologic malignancies (e.g., lymphoma)
* Hormone receptor status (for patients with breast cancer):
* Estrogen receptor-negative tumor
* Menopausal status not specified
* Karnofsky performance status 40-100%
* Life expectancy ≥ 3 months
* ALT normal
* Bilirubin normal
* Serum creatinine normal (≤ 1.8 mg/dL for males and ≤ 1.5 mg/dL for females)
* Free T4 and thyroid-stimulating hormone normal
* Not pregnant
* Negative pregnancy test
* Fertile patients must use effective contraception
* No pathologic fracture or impending fracture of the treatment site
* No history of primary hyperparathyroidism
* No malabsorptive disease or chronic diarrhea
* No history of sarcoidosis or tuberculosis
Exclusion Criteria
* Less than 30 days since prior antibiotics
* Less than 30 days since prior initiation of systemic therapy (e.g., hormonal therapy, chemotherapy, or immunotherapy)
* Less than 90 days since prior intravenous bisphosphonate therapy
* Concurrent oral bisphosphonates allowed
* Prior radiotherapy or palliative surgery to the painful sites
* Concurrent surgical fixation of the bone
* Concurrent treatment to the skull, hands, or feet
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Masonic Cancer Center, University of Minnesota
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shalamar Sibley, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Masonic Cancer Center, University of Minnesota
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UMN-0803M29541
Identifier Type: OTHER
Identifier Source: secondary_id
2008LS035
Identifier Type: -
Identifier Source: org_study_id